Focused On-demand Library for Integrator complex subunit 14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96SY0

UPID:

INT14_HUMAN

Alternative names:

von Willebrand factor A domain-containing protein 9

Alternative UPACC:

Q96SY0; B4DDI6; B4DVD5; Q49AH8; Q96HX5; Q9H0S5

Background:

Integrator complex subunit 14, also known as von Willebrand factor A domain-containing protein 9, plays a crucial role in the Integrator complex. This complex is essential for the transcription and 3'-box-dependent processing of small nuclear RNAs (snRNA) U1 and U2, pivotal in RNA splicing. The precise mechanisms and interactions of this protein within cellular processes underscore its significance in gene expression regulation.

Therapeutic significance:

Understanding the role of Integrator complex subunit 14 could open doors to potential therapeutic strategies. Its involvement in fundamental RNA processing pathways suggests that modulating its activity could offer new avenues for treating diseases linked to gene expression dysregulation.